Results 171 to 180 of about 1,757,232 (357)

Factor V Deficient Mice

Japanese Journal of Thrombosis and Hemostasis, 1997
Kengo MUTA, Jun MIZUGUCHI, Takayoshi HAMAMOTO, Sadaaki IWANAGA   +3 more
openaire   +2 more sources

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Combined Factor V and Factor VIII Deficiency: A Case Report

, 2016
Ehsan Shahverdi, Ayman K.M. Hassan, Fardin Dolatimehr, Sara Beheshtian, Shima Melatshahi Chaeichi, Avishan Masoumi   +5 more
openalex   +2 more sources

Lethal Perinatal Thrombosis in Mice Resulting From the Interaction of Tissue Factor Pathway Inhibitor Deficiency and Factor V Leiden [PDF]

, 2002
Daniel T. Eitzman, Randal J. Westrick, Xiaoming Bi, Sara L. Manning, John E. Wilkinson, George Broze, David Ginsburg   +6 more
openalex   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom [PDF]

, 2010
,, Goodship, Tim H J, Machin, Sam, Taylor, C Mark, Wigmore, Stephen J   +4 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Autoimmune Factor V Deficiency That Took 16 Years to Diagnose due to Pseudodeficiency of Multiple Coagulation Factors. [PDF]

Case Rep Med, 2021
Kato T, Hanawa T, Asou M, Asakawa T, Sakamaki H, Araki M.   +5 more
europepmc   +1 more source

Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency.

Blood, 2015
B. Bouchard, J. Chapin, K. Brummel‐Ziedins, P. Durda, N. Key, P. Tracy   +5 more
semanticscholar   +1 more source

A Case of Acquired Factor V Deficiency after Percutaneous Coronary Intervention

, 2017
Eun Sang Yu, Dae Sik Kim, Chul Won Choi
openalex   +1 more source